Tillkännagivande • 5h
Predilife S.A., Annual General Meeting, Jun 30, 2026 Predilife S.A., Annual General Meeting, Jun 30, 2026. Location: 1 rue royale bureaux de la colline, saint cloud France New Risk • May 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$856k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€11.3m market cap, or US$13.2m). New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$854k). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€13.0m market cap, or US$15.2m). Reported Earnings • Oct 12
First half 2025 earnings released First half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024). New Risk • Jul 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€13m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (€493k revenue, or US$577k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€12.1m market cap, or US$14.2m). Reported Earnings • Jun 09
Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023) Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France. Tillkännagivande • May 20
Predilife S.A., Annual General Meeting, Jun 23, 2025 Predilife S.A., Annual General Meeting, Jun 23, 2025. Location: 1 rue royale bureaux de la colline, batiment b 9e etage, saint cloud France New Risk • May 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€3.5m). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (€301k revenue, or US$334k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€14.0m market cap, or US$15.6m). New Risk • Jul 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.3m free cash flow). Share price has been highly volatile over the past 3 months (62% average weekly change). Negative equity (-€9.1m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€318k revenue, or US$345k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€22.7m market cap, or US$24.6m). New Risk • Apr 22
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$332k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.2m market cap, or US$16.2m). New Risk • Mar 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$340k). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (€16.9m market cap, or US$18.4m). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 27
Full year 2021 earnings released Full year 2021 results: Net loss: €3.41m (loss widened 52% from FY 2020). Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Sep 29
Full year 2020 earnings released: €0.64 loss per share (vs €0.71 loss in FY 2019) Full year 2020 results: Net loss: €2.25m (loss widened 7.1% from FY 2019). Is New 90 Day High Low • Jan 11
New 90-day low: €6.85 The company is down 4.0% from its price of €7.10 on 13 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 25% over the same period. Is New 90 Day High Low • Nov 06
New 90-day high: €8.30 The company is up 24% from its price of €6.70 on 07 August 2020. The French market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period. Is New 90 Day High Low • Oct 15
New 90-day high: €7.80 The company is up 20% from its price of €6.50 on 17 July 2020. The French market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. 
